A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
A placebo controlled study of two doses of HMPL-004 in patients with active mild to moderate
ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3,
taking mesalamine (or equivalent) as a concomitant medication.
The objective is to evaluate the efficacy and safety of HMPL-004 with mesalamine (mesalamine
treatment failures). Efficacy will be measured by a comparison of the proportion of patients
in each treatment group attaining clinical remission at Week 8 as compared to placebo.